Compositions and methods for depleting diseased hematopoietic stem cells
By administering specific anti-c-kit antibodies to patients to selectively deplete diseased HSCs, the problem of difficulty in targeting diseased HSCs in existing treatments is solved, the proportion of healthy HSCs is increased, side effects are reduced, and treatment efficacy is enhanced.
Patent Information
- Application Number
- CN202380029912.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-28
- Filing Date
- 2023-02-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing treatments are unable to selectively target and deplete diseased hematopoietic stem cells (HSCs), resulting in limited efficacy in treating diseases such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and conventional chemotherapy has significant side effects.
By administering anti-c-kit antibodies to patients, especially those containing specific monoclonal antibody complementarity-determining regions (CDRs), diseased HSCs are selectively consumed, the proportion of healthy HSCs is increased, the number of diseased HSCs is reduced, and the hematopoietic function of healthy HSCs is enhanced.
It achieves selective consumption of diseased HSCs, increases the proportion of healthy HSCs in the bone marrow, reduces the side effects of chemotherapy, prolongs the time patients can avoid hematopoietic cell transplantation and whole-body irradiation, and improves treatment efficacy.
Smart Images

Figure CN118922208A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 314,917, filed on February 28, 2022, which is incorporated herein by reference in its entirety.
[0003] Reference to an electronic sequence listing
[0004] The contents of the electronic sequence listing (JATH_008_01WO_SeqList_ST26.xml; size: 43,722 bytes; and creation date: February 28, 2023) are incorporated herein by reference in their entirety. Field of the Invention
[0005] The present disclosure relates to compositions and methods for depleting hematopoietic stem cells (HSCs). The compositions and methods described herein can be used to treat patients who need to deplete diseased HSCs due to a variety of different diseases or conditions, including but not limited to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Background Art
[0006] Myelodysplastic syndrome (MDS) is a blood malignancy characterized by the presence of defective hematopoietic stem cells (HSC). Current treatments for MDS include hematopoietic stimulants for temporary relief of associated symptoms. These treatments may include long-term blood transfusions, erythropoietin stimulators, or various chemotherapy. However, there is currently no treatment method for specifically targeting diseased HSC relative to healthy HSC. Therefore, innovative agents and therapies are needed that selectively target diseased HSC and allow healthy HSC to perform normal hematopoiesis in the bone marrow. The present disclosure meets this demand by providing reagents and protocols for selectively depleting diseased HSC in MDS, acute myeloid leukemia (AML), and other conditions. Summary of the invention
[0007] The present disclosure provides, inter alia, a method of depleting diseased hematopoietic stem cells (HSCs) relative to healthy HSCs by administering an anti-c-kit antibody to a patient. In a specific embodiment, diseased HSCs are selectively depleted compared to healthy HSCs.
[0008] In one aspect, the present disclosure provides a method of depleting endogenous diseased hematopoietic stem cells (HSC) in a subject, comprising administering an anti-c-kit antibody to the subject, wherein the method increases the percentage of healthy hematopoietic stem cells (HSC) present in the subject's bone marrow, such as immediately after the end of treatment, or about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks, 1 month, 2 months, 4 months, or 6 months after the end of treatment. In a specific embodiment, diseased HSCs are selectively depleted. In a specific embodiment, the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a monoclonal antibody selected from the group consisting of SR-1, JSP191, MGTA-117, FSI-174, CDX0158, CDX0159, 8D7, K45, 104D2, CK6, AB249, YB5.B8, AF-2-1, AF11, AF12, AF112, AF-3, AF-1-1, NF, NF-2-1, NF11, NF12, NF112, NF-3, HF11, HF12, and HF112, optionally JSP191, CDX0158, CDX0159, or FSI-174. In specific embodiments, the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a humanized form of a monoclonal antibody selected from the group consisting of: ACK2, ACK4, 2B8, 3C11, MR-1, and CD122. In certain embodiments, the anti-c-kit antibody comprises the CDRs of an antibody that blocks binding of stem cell factor (SCF) to stem cell factor receptor (CD117), optionally wherein the antibody is JSP191.
[0009] In a specific embodiment, about 0.01 mg / kg to about 20 mg / kg of anti-c-kit antibody is administered to the subject, optionally about 0.1 mg / kg to about 10 mg / kg of anti-c-kit antibody. In a specific embodiment of any method disclosed herein, about 0.6 mg / kg of anti-c-kit antibody is administered to the subject. In a specific embodiment, about 2 mg / kg of anti-c-kit antibody is administered to the subject. In a specific embodiment, the anti-c-kit antibody is systemically delivered to the subject, optionally wherein the anti-c-kit antibody is delivered intravenously or subcutaneously. In a specific embodiment, the anti-c-kit antibody is locally delivered to the subject, optionally wherein the anti-c-kit antibody is delivered directly to the bone marrow. In a specific embodiment, two or more doses of anti-c-kit antibody are administered to the subject. In specific embodiments, one of the two or more doses is administered about every week, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, about every 9 weeks, about every 10 weeks, about every 11 weeks, or about every 12 weeks, optionally wherein the time intervals between each dose are different. In specific embodiments, prior to treatment, the subject's bone marrow comprises at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, or at least 20% healthy HSCs.
[0010] In a specific embodiment of any method disclosed herein, the method is used to treat a disease or condition selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma, non-Hodgkin's lymphoma, clonal hematopoiesis of uncertain potential (CHIP), clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndrome (MDS), idiopathic cytopenia of undetermined significance (ICUS) and myeloproliferative neoplasms (MPN). In a specific embodiment, the disease or condition is MDS. In a specific embodiment, MDS is a lower risk MDS. In a specific embodiment, the subject has experienced erythropoiesis stimulating agent (ESA) therapy failure, optionally wherein ESA therapy comprises erythropoietin and / or Darbepoetin. In a specific embodiment, the method has reduced side effects compared to treatment with a chemotherapeutic agent, optionally wherein the chemotherapeutic agent includes azacytidine, lenalidomide, decitabine and / or Luspatercept. In a specific embodiment, the reduced side effects include lower risk of hematological toxicity and lower risk of death from infection. In a specific embodiment, the method increases the percentage of normal HSC in the bone marrow to at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 100% of all HSC, and optionally wherein the method increases the long-term advantage of healthy hematopoietic stem cells (HSC) in the subject's bone marrow. In a specific embodiment, the subject does not need or have hematopoietic cell transplantation (HCT) for at least 4 months, at least 6 months, at least 1 year, or at least 2 years after administration of an anti-c-kit antibody.
[0011] On the other hand, the present disclosure provides a method for treating a disease or condition (optionally myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)) in a subject, the method comprising administering to the subject an effective dose of an anti-c-kit antibody to achieve a long-term advantage of healthy hematopoietic stem cells (HSC) in the subject's bone marrow. In specific embodiments, the disease or condition is myelodysplastic syndrome (MDS). In specific embodiments, MDS is a lower risk MDS. In specific embodiments, the disease or condition is acute myeloid leukemia (AML). In specific embodiments, the subject has experienced failure of erythropoiesis stimulating agent (ESA) therapy, optionally wherein the ESA therapy comprises erythropoietin and / or darbepoetin. In specific embodiments, the method selectively consumes diseased HSCs compared to healthy HSCs. In a specific embodiment, the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a monoclonal antibody selected from the group consisting of SR-1, JSP191, MGTA-117, FSI-174, CDX-0159, 8D7, K45, 104D2, CK6, AB249, YB5.B8, AF-2-1, AF11, AF12, AF112, AF-3, AF-1-1, NF, NF-2-1, NF11, NF12, NF112, NF-3, HF11, HF12, and HF112. In a specific embodiment, the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a humanized form of a monoclonal antibody selected from the group consisting of ACK2, ACK4, 2B8, 3C11, MR-1, and CD122. In specific embodiments, the anti-c-kit antibody comprises the CDRs of an antibody that blocks binding of stem cell factor (SCF) to stem cell factor receptor (CD117), optionally wherein the antibody is JSP191.
[0012] In a specific embodiment of the method disclosed herein, about 0.01 mg / kg to about 10 mg / kg of anti-c-kit antibody is administered to the subject, and about 0.1 mg / kg to about 10 mg / kg of anti-c-kit antibody is optionally administered. In a specific embodiment, about 0.6 mg / kg of anti-c-kit antibody is administered to the subject. In a specific embodiment, about 2 mg / kg of anti-c-kit antibody is administered to the subject. In a specific embodiment, the anti-c-kit antibody is systemically delivered to the subject, optionally wherein the anti-c-kit antibody is delivered intravenously or subcutaneously. In a specific embodiment, the anti-c-kit antibody is locally delivered to the subject, optionally wherein the anti-c-kit antibody is delivered directly to the bone marrow. In a specific embodiment, two or more doses of anti-c-kit antibody are administered to the subject. In a specific embodiment, one of two or more doses is administered weekly, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, every 11 weeks, or every 12 weeks, optionally wherein the time intervals between the doses are different. In specific embodiments, prior to treatment, the subject's bone marrow contains at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, or at least 20% healthy HSCs.
[0013] In a specific embodiment, the methods disclosed herein have reduced side effects compared to treatment with a chemotherapeutic agent, optionally wherein the chemotherapeutic agent includes azacytidine, lenalidomide, decitabine and / or rotercept. In a specific embodiment, the reduced side effects are lower risk of hematological toxicity and lower risk of death from infection. In a specific embodiment, the method increases the percentage of normal HSC in the bone marrow to at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 100% of all HSC. In a specific embodiment, the subject has not undergone hematopoietic cell transplantation (HCT) for at least 4 months, at least 6 months, at least 1 year or at least 2 years after administration of an anti-c-kit antibody. In a specific embodiment, an anti-c-kit antibody (eg, JSP191) is administered in combination with an anti-CD47 antibody, for example, for the treatment of AML. In a specific embodiment, an anti-c-kit antibody is administered in combination with a chemotherapeutic agent. In a specific embodiment, the chemotherapeutic agent is azacytidine, for example, for the treatment of MDS. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 is a schematic diagram of the effect of administration of an exemplary anti-c-kit antibody (eg, JSP191) on hematopoiesis of normal and diseased cells in patients with hematological malignancies, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
[0015] Figure 2 is a bar graph of percent (%) depletion of CD34+CD45RA-CD117+ cells measured 10-14 days after treatment in nine myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients treated with a single dose of anti-c-kit antibody.
[0016] Figure 3 is a flow chart showing an exemplary target patient population (eg, low-risk myelodysplastic syndrome (MDS) patients) for anti-c-kit antibody therapy to deplete diseased hematopoietic stem cells (HSCs). DETAILED DESCRIPTION
[0017] The present disclosure provides treatments for myelodysplastic syndrome (MDS), MDS, acute myeloid leukemia (AML), and other patients with anti-c-kit antibodies at doses that effectively consume diseased hematopoietic stem cells (HSC) and increase the percentage of healthy HSC in the bone marrow. In specific embodiments, diseased HSC are selectively consumed. In certain embodiments, the anti-c-kit antibody treatment described herein reduces diseased HSC to a greater extent than healthy HSC, thereby reestablishing the dominance of healthy cells in the bone marrow, and thereby increasing the number of healthy HSC and reducing the need for hematopoietic stem cell transplantation (HCT), total body irradiation (TBI) and / or chemotherapy. In specific embodiments, the method achieves a long-term dominance of healthy hematopoietic stem cells (HSC) in the subject's bone marrow, such as at least six months, at least one year, at least two years, at least five years, or at least 10 years.
[0018] The treatments described herein have been shown to be effective in treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (see Examples). However, these treatments are not intended to be limited to these disease populations. The compositions and methods disclosed herein can be used to treat other diseases in which selective consumption of diseased HSCs is indicated. Related diseases or conditions include, but are not limited to, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma, non-Hodgkin's lymphoma, clonal hematopoiesis of uncertain potential (CHIP), clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndrome (MDS), idiopathic cytopenia of undetermined significance (ICUS), and myeloproliferative neoplasms (MPN).
[0019] It should be understood that the present invention is not limited to the specific methods, products, equipment and factors described, as these methods, equipment and formulations can certainly vary. It should also be understood that the terminology used herein is only for the purpose of describing specific embodiments and is not intended to limit the scope of the present invention, which is limited only by the appended claims.
[0020] It must be noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a candidate drug" refers to one or a mixture of such candidate drugs, and reference to "a method" includes reference to equivalent steps and methods known to those skilled in the art, and so forth.
[0021] Unless otherwise defined herein, the scientific and technical terms used in this application should have the meanings commonly understood by those of ordinary skill in the art. In general, the terms and techniques associated with chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry described herein are well known and commonly used in the art.
[0022] Where a numerical range is provided, it is understood that unless the context clearly dictates otherwise, each intervening value to one tenth of the unit of the lower limit between the upper and lower limits of the range, as well as any other specified value or intervening value within the specified range, is encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges and are also encompassed within the present invention, subject to any specifically excluded limitations within the range. When the range includes one or both limits, ranges excluding one or both of these included limits are also encompassed within the present invention.
[0023] As used herein, "antibody" includes reference to immunoglobulin molecules that immunoreact with a specific antigen, and includes polyclonal antibodies and monoclonal antibodies. The term also includes genetically engineered forms, such as humanized antibodies, chimeric antibodies (e.g., humanized mouse antibodies), and heteroconjugate antibodies. The term "antibody" also includes antigen-binding forms of antibodies, including fragments with antigen-binding ability (e.g., Fab', F(ab')2, Fab, Fv, and rIgG. The term also refers to recombinant single-chain Fv fragments (scFv). The term antibody also includes bivalent or bispecific molecules, diabodies, triabodies, and tetrabodies.
[0024] "Humanized antibody" is an immunoglobulin molecule that contains a minor sequence from a non-human immunoglobulin. Humanized antibodies include human immunoglobulins (receptor antibodies) in which residues from the complementary determining region (CDR) of the receptor are replaced by residues from the CDR of a non-human species (donor antibody) such as a mouse, rat or rabbit and having the desired specificity, affinity and ability. In some cases, the Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also include residues that are neither present in the receptor antibody nor in the imported CDR or framework sequence. In general, humanized antibodies will include substantially all of at least one, usually two variable domains, wherein all or substantially all of the CDR regions correspond to those of non-human immunoglobulins, and all or substantially all of the framework (FR) regions are those of the consensus sequence of human immunoglobulins. Humanized antibodies preferably also include at least a portion of an immunoglobulin constant region (Fc), usually a constant region of a human immunoglobulin.
[0025] The selection of antibodies for endogenous stem cell ablation can be based on a variety of criteria, including selectivity, affinity, cytotoxicity, etc. When referring to proteins or peptides, the phrase "specifically (or selectively) binds" to an antibody refers to a binding reaction that determines the presence of a protein in a heterogeneous population of proteins and / or other biologicals. Thus, under specified immunoassay conditions, the binding of a given antibody to a particular protein sequence is at least twice the background binding, and more typically more than 10 to 100 times the background binding.
[0026] Monoclonal antibodies can be prepared using the hybridoma method. In the hybridoma method, a suitable host animal is usually immunized with an immunizing agent to induce lymphocytes that produce or are capable of producing antibodies that specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro. Lymphocytes are then fused with an immortalized cell line using a suitable fusing agent such as polyethylene glycol to form hybridoma cells.
[0027] Various techniques known in the art (including phage display libraries) can be used to produce human antibodies. Similarly, human antibodies can be prepared by introducing human immunoglobulin loci into transgenic animals, such as mice in which endogenous immunoglobulin genes have been partially or completely inactivated. After the attack, the production of human antibodies is observed, which is very similar to that observed in humans in all aspects, including gene rearrangement, assembly and antibody repertoires.
[0028] Antibodies also exist in the form of many well-characterized fragments, which are produced by digestion with various peptidases. Pepsin digests the antibody hinge region below the disulfide bond to produce a dimer F(ab)'2 of Fab, which itself is a light chain connected to VH-CH1 by a disulfide bond. F(ab)'2 can be reduced under mild conditions to destroy the disulfide bond in the hinge region, thereby converting the F(ab)'2 dimer into a Fab' monomer. Fab' monomer is basically a Fab with a partial hinge region. Although various antibody fragments are defined based on the digestion of intact antibodies, technicians will understand that these fragments can be synthesized chemically or de novo using recombinant DNA methods. Therefore, as used herein, the term antibody also includes antibody fragments produced by modifying intact antibodies, or antibody fragments (e.g., single-chain Fv) synthesized anew using a recombinant DNA method, or antibody fragments identified using a phage display library.
[0029] The selectivity of a particular antibody is often determined by the ability of one antibody to competitively inhibit the binding of a second antibody to the antigen, or by the ability of the antibody to cross-react with multiple epitopes. Any of a number of competitive binding assays can be used to measure the competition of two antibodies for the same antigen, or the competition of two antigens for one antibody. An exemplary assay is the BIACORE TM Assays. Briefly, in these assays, binding sites can be structurally mapped by testing the ability of interactors (e.g., different antibodies) to inhibit the binding of another. Injecting two consecutive antibody or antigen samples of sufficient concentration can identify paired competing antibodies for the same binding epitope. The antibody sample should have the potential to reach significant saturation at each injection. The net binding of the second antibody injection indicates the binding epitope analysis. Due to different epitopes, two levels of reaction can be used to describe the boundaries of complete competition and non-competitive binding. The relative amount of the binding reaction of the second antibody injection relative to the binding of the same and different binding epitopes determines the degree of epitope overlap.
[0030] The term "polynucleotide" refers to a polymeric form of nucleotides of any length, including deoxyribonucleotides or ribonucleotides, or analogs or mixtures thereof. A polynucleotide may include modified nucleotides, such as methylated nucleotides and nucleotide or nucleoside analogs, and may be interrupted by non-nucleotide components. If present, the nucleotide structure may be modified before or after polymer assembly. As used herein, the term polynucleotide includes, but is not limited to, double-stranded and single-stranded molecules and mixtures thereof. Unless otherwise specified or required, any embodiment of the invention as described herein as a polynucleotide encompasses each of the two complementary single-stranded forms known or predicted to constitute the double-stranded form, whether RNA or DNA, or a mixture thereof.
[0031] As used herein, the terms "polypeptide", "peptide" and "protein" refer to polymers of amino acids of any length. The terms also encompass modified amino acid polymers; for example, including disulfide bond formation, glycosylation, lipidation, phosphorylation or conjugation with a labeling component.
[0032] As used herein, with respect to a polypeptide or polynucleotide sequence of interest, the terms "identity" and "identical" refer to the percentage of exact matching residues in an alignment of the sequence of interest with a reference sequence, such as an alignment generated by the BLAST algorithm. Unless otherwise indicated, identity is calculated over the full length of the reference sequence. Thus, if at least x% (rounded down) of the residues in the subject sequence are exactly matched to the corresponding residues in the query sequence when the reference sequence (as the query sequence) is aligned with the sequence of interest (as the subject sequence), the sequence of interest "shares at least x% identity" with the reference sequence, the denominator being the full length of the reference sequence plus the length of any gap inserted into the reference sequence obtained by aligning the reference sequence with the sequence of interest. When the subject sequence has variable positions (e.g., residues marked as X), the alignment with any residue in the query sequence is considered a match. Sequence similarity (i.e., identity) can be determined in many different ways. To determine sequence identity, sequences can be aligned using methods and computer programs including BLAST, which can be obtained on the World Wide Web at ncbi.nlm.nih.gov / BLAST / . Sequence alignments may be performed using the NCBI Blast service (BLAST+ version 2.12.0) or another program that produces the same results. Unless indicated to the contrary, sequence identity is determined using the BLAST algorithm (e.g. bl2seq) and default parameters.
[0033] As used herein, the term "native" or "wild type" refers to a nucleotide sequence (e.g., a gene) or a gene product (e.g., an RNA or polypeptide) present in a wild-type cell, tissue, organ, or organism. As used herein, the term "variant" refers to a reference polynucleotide or polypeptide sequence, such as a mutant of a natural polynucleotide or polypeptide sequence, i.e., having less than 100% sequence identity with the reference polynucleotide or polypeptide sequence. In other words, relative to a reference polynucleotide sequence, such as a natural polynucleotide or polypeptide sequence, the variant comprises at least one amino acid difference (e.g., an amino acid substitution, an amino acid insertion, an amino acid deletion). For example, a variant can be a polynucleotide having 50% or more, 60% or more, or 70% or more sequence identity with a full-length natural polynucleotide sequence, for example, 75% or 80% or more, such as 85%, 90% or 95% or more identity, for example 98% or 99% identity with a full-length natural polynucleotide sequence. As another example, a variant can be a polypeptide having 70% or more sequence identity to a full-length native polypeptide sequence, such as 75% or 80% or more, such as 85%, 90% or 95% or more identity, such as 98% or 99% identity to a full-length native polypeptide sequence. Variants can also include variant fragments of a reference sequence (e.g., a native sequence) having 70% or more sequence identity, such as 75% or 80% or more, such as 85%, 90% or 95% or more identity, such as 98% or 99% identity to a fragment of a reference sequence (e.g., a native sequence).
[0034] As used herein, the term "stem cell" refers to a mammalian cell that has the ability to self-renew and produce differentiated progeny (see Morrison et al. (1997) Cell 88: 287-298). Endogenous stem cells can be characterized by the presence of markers associated with specific epitopes. As used herein, the term "hematopoietic stem cell (HSC)" refers to a multipotent cell that resides in the bone marrow (BM) and is responsible for the lifelong production of mature blood cells.
[0035] The terms "treatment / treating" and the like are generally used herein to mean obtaining a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, such as reducing the likelihood of the disease or its symptoms occurring in a subject, and / or in terms of partially or completely curing a disease and / or the side effects caused by the disease, the effect may be therapeutic. As used herein, "treatment" includes any treatment for a mammalian disease, and includes: (a) inhibiting the disease, i.e., preventing its development; or (b) alleviating the disease, i.e., causing the disease to regress. The therapeutic agent may be administered before, during, or after the onset of the disease or injury. The treatment of an ongoing disease is particularly interesting, wherein the treatment stabilizes or reduces the patient's adverse clinical symptoms. This treatment is ideally performed before the complete loss of function of the affected tissue. The subject therapy may be administered before or during the symptomatic stage of the disease, and in some cases after the symptomatic stage of the disease.
[0036] The terms "individual," "host," "subject," and "patient" are used interchangeably herein and refer to mammals, including but not limited to humans and non-human primates, including monkeys and humans; mammalian sport animals (e.g., horses); mammalian farm animals (e.g., sheep, goats, etc.); mammalian pets (dogs, cats, etc.); and rodents (e.g., mice, rats, etc.).
[0037] As used herein, the term "substantially" means significantly or in large quantities or to a great extent. For example, "substantially" increase may mean an increase of at least two times, at least three times, at least four times, at least five times or at least ten times, and "substantially" reduction may mean a reduction of at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%. In the following description, many specific details are set forth to provide a more thorough understanding of the present invention. However, it is clear to those skilled in the art that the present invention can be implemented without one or more of these specific details. In other cases, in order to avoid blurring the present invention, well-known features and procedures well known to those skilled in the art are not described.
[0038] Generally, the present invention adopts conventional methods of protein synthesis, recombinant cell culture and protein isolation and recombinant DNA technology within the technical scope of the art. Such technology is fully explained in the literature, see for example Maniatis, Fritsch and Sambrook, Molecular Cloning: A Laboratory Manual (1982); Sambrook, Russell and Sambrook, Molecular Cloning: A Laboratory Manual (2001); Harlow, Lane and Harlow, Using Antibodies: A Laboratory Manual: Portable Protocol Vol. I, Cold Spring Harbor Laboratory (1998); and Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory; (1988).
[0039] I. Depletion of diseased HSCs
[0040] In some embodiments, the treatment described herein depletes diseased hematopoietic stem cells (HSC) from the bone marrow of a subject. In some embodiments, "disease HSC" is HSC that is not differentiated or has a significantly reduced differentiation ability, does not divide or has a significantly reduced cell division ability, cannot produce functional blood cells, or has a significantly reduced amount of functional blood cells produced and / or is otherwise classified as a hematological malignancy. In certain embodiments, a significant difference is a statistically significant difference with a p-value of 5% or less. In some embodiments, the present disclosure provides a method for selectively depleting endogenous diseased hematopoietic stem cells (HSC) in a subject, and / or a method for increasing the relative percentage of healthy HSC, which is performed by administering an anti-c-kit antibody.
[0041] In some embodiments, the treatment described herein depletes diseased HSCs in a subject. In some embodiments, depleting diseased HSCs refers to depleting about 2%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, about 99% or about 100% of the total diseased HSCs in a subject.
[0042] In some embodiments, the treatments described herein selectively deplete diseased HSCs in a subject. In specific embodiments, selective depletion of diseased HSCs according to the disclosed methods results in a greater number or percentage of diseased HSCs being depleted compared to the number or percentage of non-diseased or healthy HSCs being depleted.
[0043] In some embodiments, treatment as described herein increases the relative percentage of healthy HSC in a subject. In some embodiments, treatment as described herein increases the relative percentage of healthy HSC in a subject (relative to total HSC) by about 50%, about 60%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900% or about 1000%.
[0044] Anti-c-Kit Antibody
[0045] In some embodiments, the present disclosure provides a method for selectively depleting endogenous diseased hematopoietic stem cells (HSC) of a subject and / or increasing the relative percentage of healthy HSC by administering an anti-c-kit antibody. In some embodiments, the compositions and methods disclosed herein may be applicable to any anti-c-kit antibody that blocks the binding of stem cell factor (SCF) to the c-kit / CD117 protein of endogenous HSC. In some embodiments, the antibody is a monoclonal anti-human c-kit antibody. In some embodiments, the antibody is an antigen-binding fragment of an antibody that blocks the binding of stem cell factor (SCF).
[0046] Many antibodies specifically binding to human CD117 contemplated by the present disclosure are known in the art and / or commercially available, including but not limited to JSP-191, SR1, 2B8, ACK2, YB5-B8, 57A5 and 104D2. In certain embodiments, the anti-c-kit antibody is selected from the group consisting of: JSP191 (Jasper Therapeutics; Redwood City, CA); CDX-0158 (formerly KTN0158) or CDX-0159 (Celldex Therapeutics, Hampton, NJ); MGTA-117 (AB85) (Magenta Therapeutics, Cambridge, MA); CK6 (Magenta Therapeutics, Cambridge, MA); AB249 (Magenta Therapeutics, Cambridge, MA); and FSI-174 (Gilead, Foster City, CA). Antibodies from Magenta Therapeutics contemplated by the present disclosure include, but are not limited to, those disclosed in U.S. Patent Application Publication No. 20190153114, PCT Application Publication No. WO2019084064, WO2020 / 219748, and WO2020 / 219770. FSI-174 antibodies are disclosed in PCT Application Publication No. WO2020 / 112687 and U.S. Patent Application Publication No. 20200165337. The present disclosure includes, but is not limited to, any anti-c-kit antibody and / or CDR set disclosed in any patent application disclosed herein, all of which are incorporated herein by reference in their entirety.
[0047] In certain embodiments, the anti-c-kit antibody binds to the extracellular region of CD117, i.e., amino acids 26-524. The sequence of this region is shown below:
[0048] QPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTP(SEQ ID NO:1).
[0049] Illustrative anti-c-kit antibodies include, but are not limited to, SR-1, JSP191, 8D7, K45, 104D2, CK6, YB5-B8, AF-2-1, AF11, AF12, AF112, AF-3, AF-1-1, NF, NF-2-1, NF11, NF12, NF112, NF-3, HF11, HF12, and HF112. Many antibodies specifically binding to human CD117 contemplated by the present disclosure are commercially available, including, but not limited to, SR1, 2B8, ACK2, YB5-B8, 57A5, 104D2, and the like. In certain embodiments, the anti-c-kit antibody is selected from the group consisting of JSP191, CDX-0159 (from Celldex Therapeutics, Hampton, NJ), MGTA-117 (AB85) (from Magenta Therapeutics, Cambridge, MA), CK6 (from Magenta Therapeutics, Cambridge, MA), AB249 (from Magenta Therapeutics, Cambridge, MA) and FSI-174 (from Gilead, South San Francisco, CA). The antibodies from Magenta Therapeutics are disclosed in U.S. Patent Application Publication No. 20190153114. In certain embodiments, the antibody is an antibody disclosed in any one of U.S. Patent Nos. 7,915,391, US 8,436,150 or US8,791,249. In certain embodiments, the antibody is an antibody disclosed in any of U.S. Patent Publication No. 20200165337 or PCT Publication Nos. WO 2020 / 112687, WO 2020 / 219748, WO 2020 / 219770, or WO 2019 / 084064.
[0050] In a specific embodiment, the antibody is a humanized form of the mouse anti-c-kit antibody SR1 described in U.S. Patents 5,919,911 and 5,489,516. The humanized form JSP191 is disclosed in U.S. Patents Nos. 7,915,391, 8,436,150 and 8,791,249. JSP191 is a deglycosylated IgG1 humanized antibody. JSP191 specifically binds to the stem cell factor (SCF) receptor human CD117, which is expressed on the surface of hematopoietic stem cells and progenitor cells. JSP191 blocks SCF from binding to CD117 and destroys stem cell factor (SCF) signaling, thereby causing hematopoietic stem cell consumption. JSP191 is a heterotetramer consisting of 2 heavy chains of the IgG1 subclass and 2 light chains of the κ subclass, and the heavy and light chains are covalently linked by disulfide bonds. Due to the intentional substitution of asparagine for glutamine at heavy chain residue 297, there are no N-linked polysaccharides on JSP191. The heavy and light chain sequences of JSP191 are disclosed as SEQ ID NO: 4 from US8436150 and SEQ ID NO: 2 from US8436150, respectively.
[0051] The heavy chain and light chain sequences of JSP191 are disclosed as SEQ ID NO: 4 from U.S. Pat. No. 8,436,150 and SEQ ID NO: 2 from U.S. Pat. No. 8,436,150, respectively. The sequences of the heavy chain and light chain of JSP191 are:
[0052] Heavy Chain:
[0053] MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:2)
[0054] and
[0055] Light chain:
[0056] MVLQTQVFISLLLWISGAYGDIVMTQSPDSLAVSLGERATINCRASESVDIYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:3).
[0057] In certain embodiments, the variable heavy domain of JSP191 comprises the following sequence:
[0058] QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQG LEWMGVIYSGNGDTSYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAV YYCARERDTRFGNWGQGTLVTVSS (SEQ ID NO: 4).
[0059] In certain embodiments, the variable light chain domain of JSP191 comprises the following sequence:
[0060] DIVMTQSPDSLAVSLGERATINCRASESVDIYGNSFMHWYQQKPGQ PPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNE DP YTFGGGTKVEIK (SEQ ID NO: 5).
[0061] The CDRs present in JSP191 are as follows: VH CDR1 = YNMH (SEQ ID NO: 6); VH CDR2 = IYSGNGDTSYNQKFKG (SEQ ID NO: 7); VH CDR3 = ERDTRFGN (SEQ ID NO: 8); VL CDR1 = RASESVDIYGNSFMH (SEQ ID NO: 9); VL CDR2 = LASNLES (SEQ ID NO: 10); and VL CDR3 = QQNNEDPYT (SEQ ID NO: 11).
[0062] CDX-0159 is a humanized monoclonal antibody that specifically binds to the receptor tyrosine kinase KIT with high specificity and effectively inhibits its activity. CDX-0159 is designed to block KIT activation by disrupting SCF binding and KIT dimerization. CDX-0159 and other anti-c-kit antibodies are described in U.S. Patent No. 10,781,267, and in specific embodiments, the anti-c-kit disclosed herein comprises the CDRs of any antibody disclosed herein. In certain embodiments, the anti-c-kit antibody comprises: (i) a light chain variable region ("VL") comprising the following amino acid sequence:
[0063] DIVMTQSPSX K1 LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX K2 LIYSASYRYSGVPDRFX K3 GSGSGTDFTLTISSLQX K4 EDFAX K5 YXK6 CQQYNSYPRTFGGGTKVEIK (SEQ ID NO: 12), wherein X K1 is an amino acid with an aromatic or aliphatic hydroxyl side chain, X K2 is an amino acid with an aliphatic or aliphatic hydroxyl side chain, X K3 is an amino acid X with an aliphatic hydroxyl side chain K4 is an amino acid with an aliphatic hydroxyl side chain or P, X K5 is an amino acid with a charged or acidic side chain, and X K6 is an amino acid with an aromatic side chain; and (ii) a heavy chain variable region ("VH") comprising the following amino acid sequence: QVQLVQSGAEX H1 KKPGASVKX H2 SCKASGYTFTDYYINAVVX H3 QAPGKGLEWIARIYPGSGNTYYNEKFKGRX H4 TX H5 TAX H6 KSTSTAYMX H7 LSSLRSEDX H8 AVYFCARGVYYFDYWGQGTTVTVSS (SEQ ID NO: 13), wherein X H1 is an amino acid with an aliphatic side chain, X H2 is an amino acid with an aliphatic side chain, X H3 is an amino acid with a polar or basic side chain, X H4 is an amino acid with an aliphatic side chain, X H5 is an amino acid with an aliphatic side chain, X H6 is an amino acid with an acidic side chain, X H7 is an amino acid having an acidic or amide derivative side chain, and X H8 is an amino acid with an aliphatic hydroxyl side chain. In specific aspects, described herein are antibodies (e.g., human antibodies or humanized antibodies), including antigen-binding fragments thereof: (i) a VH CDR of a VH domain comprising the amino acid sequence QVQLKQSGAELVRPGASVKLSCKASGYTFTDYYINWVKQRPGQGLEWIARIYPG
[0064] SGNTYYNEKFKGKATLTAEKSSSTAYMQLSSLTSEDSAVYFCARGVYYFDYWGQ GTTLTVSS(SEQID NO:14)or
[0065] QVQLKQSGAELVRPGASVKLSCKASGYTFTDYYINWVKQRPGQGL
[0066] EWIARIYPG
[0067] SGNTYYNEKFKGKATLTAEKSSSTAYMQLSSSLTSEDSAVYFCARGVYYFDYWGQ GTTLTVSA(SEQID NO:15), and
[0068] (ii) a VL CDR of a VL domain comprising the amino acid sequence DIVMTQSQKFMSTSVGDRVSVTCKASQNVRTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNSYPRTFGGGTKLEIKR (SEQ ID NO: 16).
[0069] MGTA-117 (AB85) is a CD117-targeted antibody engineered for the transplant environment and conjugated to amanitin, which is developed for patients undergoing immune resetting through autologous or allogeneic stem cell transplantation. MGTA-117 depletes hematopoietic stem and progenitor cells, and this antibody and other antibodies contemplated by the present disclosure are described in U.S. Application Publication No. 20200407440 and / or PCT Application Publication No. WO2019084064. Epitope analysis of AB85 binding to CD177 is described in PCT Application Publication No. WO2020219770, which identified the following two epitopes in CD117:
[0070] EKAEATNTGKYTCTNKHGLSNSIYVFVRDPA (SEQ ID NO: 17; amino acids 60-90), and
[0071] RCPLTDPEVTNYSLKGCQGKP (SEQ ID NO: 18; amino acids 100-130).
[0072] The sequences of the variable heavy chain and variable light chain of AB85 are disclosed as SEQ ID NO: 143 and SEQ ID NO: 144, respectively, from PCT Application Publication No. WO2019084064.
[0073] The amino acid sequence of the heavy chain variable region (VH) of Ab85 is:
[0074] EVQLVQSGAEVKKPGESLKISCKGSGYSFT NYWIG WVRQMPGKGL EWMA IINPRDSDTRYRPSFQG QVTISADKSISTAYLQWSSLKASDTAMYY CAR HGRGYEGYEGAFDI WGQGTLVTVSS (SEQ ID NO: 19).
[0075] The VH CDR amino acid sequences of AB85 are as follows: NYWIG (SEQ ID NO:20; VH CDR1); IINPRDSDTRYRPSFQG (SEQ ID NO:21; VH CDR2); and HGRGYEGYEGAFDI (SEQ ID NO:22; VH CDR3).
[0076] The amino acid sequence of the light chain variable region (VL) of AB85 is:
[0077] DIQMTQSPSSLSASVGDRVTITC RSSQGIRSDLG WYQQKPGKAPKLL IY DASNLET GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQANGFPLT F GGGTKVEIK (SEQ ID NO: 23).
[0078] The VL CDR amino acid sequences of AB85 are as follows: RSSQGIRSDLG (SEQ ID NO:24; VL CDR1); DASNLET (SEQ ID NO:25; VL CDR2); and QQANGFPLT (SEQ ID NO:26; VL CDR3).
[0079] FSI-174 is an anti-cKIT antibody that is being developed in combination with 5F9 as a non-toxic transplant conditioning regimen and for targeted treatment of hematopoietic malignancies. The sequence of FSI-174 is disclosed in PCT Application Publication No. 2020 / 112687, U.S. Patent Application Publication No. 20200165337, and U.S. Patent No. 11,041,022. In a specific embodiment, the anti-c-kit antibody comprises three CDRs or variable heavy chain regions present in any of AH1, AH2, AH3, AH4, or AH5 disclosed therein, and / or three CDRs or variable heavy chain regions present in any of AL1 or AL2 disclosed therein.
[0080] In certain embodiments, the CDRs present in FSI-174 and related antibodies are as follows: VH CDR1 = SYNMH (SEQ ID NO: 27); VH CDR2 = VIYSGNGDTSY (A / N) QKF (K / Q) G (SEQ ID NO: 28); VH CDR3 = ERDTRFGN (SEQ ID NO: 29); VL CDR1 = RAS (D / E) SVDIYG (N / Q) SFMH (SEQ ID NO: 30); VL CDR2 = LASNLES (SEQ ID NO: 31); and VL CDR3 = QQNNEDPYT (SEQ ID NO: 32). A / N, etc. means that the amino acid position can be either of the two amino acids, in this example A or N. In certain embodiments, the CDRs present in the heavy variable region are CDR H1, H2, and H3, as defined by Kabat: H1 = SYNMH (SEQ ID NO:27); H2 = VIYSGNGDTSYAQKFKG (SEQ ID NO:33); H3 = ERDTRFGN (SEQ ID NO:29); and the CDRs present in the light variable region are CDR L1, L2, and L3, as defined by Kabat: L1 = RASESVDIYGQSFMH (SEQ ID NO:34); L2 = LASNLES (SEQ ID NO:31); and L3 = QQNNEDPYT (SEQ ID NO:32), respectively, except that there are 1, 2, or 3 CDR residue substitutions selected from N to A at heavy chain position 60, K to Q at heavy chain position 64, and N to Q at light chain position 30, the positions being numbered according to Kabat. In certain embodiments, the antibody comprises any of the heavy chain variable region sequences (AH2, AH3, AH4) and / or light chain variable region sequences (AL2) provided below, or the underlined CDRs therein:
[0081] AH2:QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYMNH WVRQAPGQGLEW MG VIYSGNGDTSYAQK FKG RVTITADKSTSTAYMELSSLRSEDTAVYYC AR ERDTRFGN WGQGTLVTVSS (SEQ ID NO: 35)
[0082] AH3:QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYMNH WVRQAPGQGLEW MG VIYSGNGDTSYNQK FWfRVTITADKSTSTAYMELSSLRSEDTAVYYC AR ERDTRFGN WGQGTLVTVSS (SEQ ID NO: 36)
[0083] AH4
[0084] QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYMNH WVRQAPGQGLEW
[0085] MG VIYSGNGDTSYAQKFQG RVTITADKSTSTAYMELSSLRSEDTAVYYCAR ERDTRFGN WGQGTLVTVSS (SEQ ID NO: 37)
[0086] AL2:DIVMTQSPLSLPVTPGEPASISC RASESVDIYGQSFMH WYQQKPGQPPKLLIY LASNLES GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC QQNNEDPYT FGGGTKVEIK (SEQ ID NO: 38).
[0087] In certain embodiments, the anti-c-kit antibody comprises the entire heavy chain and / or entire light chain of any antibody disclosed herein, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with a heavy chain or light chain disclosed herein (e.g., a JSP191 heavy chain or light chain). In certain embodiments, the anti-c-kit antibody comprises the heavy chain and / or light chain variable region of any antibody disclosed herein, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with a heavy chain or light chain variable region disclosed herein, e.g., a JSP191 heavy chain or light chain variable region. In certain embodiments, the anti-c-kit antibody comprises a heavy chain and / or light chain containing one or more CDRs of an antibody disclosed herein, e.g., two, three, four, five, or six CDRs of an antibody disclosed herein (e.g., a JSP191 antibody). In a specific embodiment, the anti-c-kit antibody comprises a heavy chain or a variable region thereof comprising one, two or three heavy chain CDRs disclosed herein, such as a JSP191 heavy chain. In a specific embodiment, the anti-c-kit antibody comprises a light chain or a variable region thereof comprising one, two or three light chain CDRs disclosed herein, such as a JSP191 light chain.
[0088] CDX-0159 is a humanized monoclonal antibody that binds to the receptor tyrosine kinase KIT with high specificity and effectively inhibits its activity. CDX-0159 is designed to block KIT activation by disrupting SCF binding and KIT dimerization.
[0089] MGTA-117 is a CD117-targeted antibody engineered for the transplant setting and conjugated to amanitin, which is developed for patients undergoing immune resetting through autologous or allogeneic stem cell transplantation. MGTA-117 depletes hematopoietic stem and progenitor cells, and this antibody and other antibodies contemplated by the present disclosure are described in US20200407440.
[0090] FSI-174 is an anti-c-kit antibody that is being developed in combination with 5F9 as a non-toxic transplant conditioning regimen and for the treatment of targeted hematopoietic malignancies.
[0091] In a specific embodiment, the antibody may comprise one or more CDRs having at least 70%, 80%, 90%, 95% or 99% amino acid or nucleotide sequence identity with a CDR present in a humanized monoclonal antibody that binds to c-kit (e.g., an antibody derived from any of mouse antibodies SR1, ACK2, ACK4, 2B8, 3C11, MR-1, and CD122). In some embodiments, the antibody blocks the binding of stem cell factor (SCF) to stem cell factor receptor (CD117). Illustrative embodiments of anti-c-kit antibodies that can be used include JSP191, as well as those described in WO2007127317A2 and US20200165337A1, both of which are incorporated herein in their entirety.
[0092] In certain embodiments, the anti-c-kit antibody comprises the entire heavy chain and / or entire light chain of any antibody disclosed herein, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with a heavy chain or light chain disclosed herein (e.g., a JSP191 heavy chain or light chain). In certain embodiments, the anti-c-kit antibody comprises the heavy chain and / or light chain variable region of any antibody disclosed herein, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with a heavy chain or light chain variable region disclosed herein, e.g., a JSP191 heavy chain or light chain variable region. In certain embodiments, the anti-c-kit antibody comprises a heavy chain and / or light chain containing one or more CDRs of an antibody disclosed herein, e.g., two, three, four, five, or six CDRs of an antibody disclosed herein (e.g., a JSP191 antibody). In a specific embodiment, the anti-c-kit antibody comprises a heavy chain or a variable region thereof comprising one, two or three heavy chain CDRs disclosed herein, such as a JSP191 heavy chain. In a specific embodiment, the anti-c-kit antibody comprises a light chain or a variable region thereof comprising one, two or three light chain CDRs disclosed herein, such as a JSP191 light chain.
[0093] II. Subjects
[0094] In certain embodiments, subjects selected for anti-c-kit antibody treatment as described herein have or retain at least some healthy hematopoietic cells (HSC) to benefit from the selective consumption of diseased HSC. In some embodiments, subjects selected for anti-c-kit treatment as described herein have at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of healthy hematopoietic stem cells (HSC) as a percentage of total HSC in the bone marrow before treatment. In specific embodiments, the percentage of healthy HSC increases during treatment.
[0095] In some embodiments, the percentage of healthy hematopoietic stem cells in a subject prior to administration of an anti-c-kit therapy as described herein is assessed by bone marrow biopsy, blood cell count, or blood film.
[0096] Treatments described herein have been shown to be effective for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, these treatments are not intended to be limited to these disease populations. The compositions and methods disclosed herein can be used to treat other diseases indicating selective consumption of sick HSC. Related diseases or conditions may include, but are not limited to, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma, non-Hodgkin's lymphoma, clonal hematopoiesis of uncertain potential (CHIP), clonal hematopoiesis of undetermined significance (CCUS), myelodysplastic syndrome (MDS), idiopathic hematopoiesis of undetermined significance (ICUS) and myeloproliferative neoplasms (MPN).
[0097] In some embodiments, the disease is a blood cancer, optionally a leukemia, a lymphoma, or a myelodysplastic syndrome (MDS). In some embodiments, the disease or condition is multiple myeloma, chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), a myeloproliferative tumor, or a myeloid leukemia, such as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). In some embodiments, the disease is MDS or AML. In some embodiments, the cancer is a lymphoid leukemia, such as acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL).
[0098] In some embodiments, cancer is myelodysplastic / myeloproliferative neoplasm (MDS / MPN), such as chronic myelomonocytic leukemia (CMML). MDS / MPN has "dysplasia" and "hyperplasia" characteristics, cannot be classified as myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN), and for this reason, is classified as an overlapping syndrome (MDS / MPN) with its own unique characteristics. CMML is a blood cancer. CMML is considered to be one of myelodysplastic / myeloproliferative neoplasms (MDS / MPN), a type of chronic blood cancer in which the bone marrow of a person cannot effectively produce blood.
[0099] In some embodiments, the subject's hematopoietic cell transplantation comorbidity index (HCT-CI) is greater than or equal to 3 (Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106 (8): 2912-2919.). In some embodiments, the subject's hematopoietic cell transplantation comorbidity index (HCT-CI) is less than or equal to 3.
[0100] In some embodiments, the disease or disorder is multiple myeloma, severe combined immunodeficiency (SCID), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms, or acute myeloid leukemia (AML).
[0101] In certain embodiments, the disease treated according to the present disclosure is referred to as MDS / AML, which includes MDS and AML. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) exist along a continuous disease spectrum, starting from early MDS, which may progress to late MDS, AML, curative AML or resistant AML. The disease is characterized by the overproduction of immature blood cells. The resulting lack of mature healthy blood cells can cause anemia and increase the risk of infection and bleeding. About 5-10% of solid tumor patients treated with chemotherapy, radiotherapy or autologous stem cell transplantation develop treatment-related MDS or AML.
[0102] Myelodysplastic syndrome (MDS) is a group of hematopoietic tumors characterized by abnormal differentiation and cell morphology (i.e., dysplasia) of multipotent hematopoietic progenitor cells (i.e., stem cells) residing in the myeloid compartment of the bone marrow (BM). These abnormalities lead to ineffective hematopoiesis and hematopoiesis (i.e., lower than normal peripheral blood cell counts) of one or more myeloid progenitor cell lineages, manifested as anemia, neutropenia, and / or thrombocytopenia. The methods disclosed herein can be used to treat various forms of MDS, including but not limited to those shown in Table 1 below, which is reproduced from Chung, US Pharm. 2021; 46 (9): 39-44. In certain embodiments, the method causes hematopoiesis.
[0103] Table 1
[0104]
[0105]
[0106] BM: bone marrow MDS: myelodysplastic syndrome: WHO: World Health Organization, Source: Ref. 2.
[0107] In some embodiments, according to IPSS-R guidelines (see, e.g., Figure 3 and Greenberg et al. Revised international prognostic scoring system for myelodysplastic syndromes, Blood, Sep 20; 120(12):2454-65; 2012), subjects selected for anti-c-kit treatment of MDS as described herein are eligible for low-risk myelodysplastic syndrome (MDS). In some embodiments, subjects selected for anti-c-kit treatment as described herein are eligible for intermediate-risk MDS according to IPSS-R guidelines. In some embodiments, subjects selected for anti-c-kit treatment as described herein are eligible for higher-risk MDS according to IPSSR guidelines. In specific embodiments, lower-risk MDS patients are defined as patients with very low, low, or moderate disease risk according to IPSS-R scores ≤3.5 points, while higher-risk patients are patients with moderate risk and >3.5 points, high or very high risk according to the scoring system. In certain embodiments, the subject suffers from red blood cell transfusion dependence, thrombocytopenia, and / or neutropenia.
[0108] In some embodiments, patients, e.g., patients with CML, MDS, or AML, exhibit minimal identifiable disease (MID) and / or measurable residual disease (MRD), which can be detected by techniques including, but not limited to, cytogenetics, flow cytometry, and / or next generation sequencing (NGS).
[0109] In some embodiments, administration of the combination therapy described herein reduces or eliminates minimal residual disease (MRD) in the patient.
[0110] In some embodiments, the subject selected for anti-c-kit therapy as described herein is unresponsive to an erythropoietin stimulating agent (ESA). In some embodiments, the ESA is erythropoietin. In some embodiments, the ESA is darbepoietin.
[0111] In some embodiments, the subject selected for anti-c-kit treatment as described herein is unresponsive to chemotherapy. In some embodiments, the chemotherapy is azacytidine, lenalidomide, decitabine, and / or rotercept.
[0112] III. Dosage and Administration
[0113] According to embodiments of the methods disclosed herein, diseased HSCs are selectively consumed at lower doses and dosing frequencies relative to healthy HSCs. Thus, in specific embodiments, the anti-c-kit treatments described herein are administered with a dosing regimen that preferentially consumes diseased HSCs relative to healthy cells, thereby providing healthy cell dominance and hematopoiesis in the bone marrow. Thus, the methods disclosed herein can be used to preferentially consume diseased HSCs (as opposed to healthy HSCs) in a subject.
[0114] In some embodiments, the anti-c-kit antibody is administered to a subject in need thereof at a dose of about 0.01 mg / kg to about 20 mg / kg. In some embodiments, the anti-c-kit antibody is any one of SR-1, JSP191, MGTA-117, FSI-174, CDX-0159, 8D7, K45, 104D2, CK6, AB249, YB5.B8, AF-2-1, AF11, AF12, AF112, AF-3, AF-1-1, NF, NF-2-1, NF11, NF12, NF112, NF-3, HF11, HF12, and HF112, and the dosage administered is about 0.01 mg / kg to about 20 mg / kg of the subject's body weight. In some embodiments, the anti-c-kit antibody is administered at a dose of about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, about 1.0 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, about 1.3 mg / kg, about 1.4 mg / kg, about 1.5 mg / kg, About 1.6 mg / kg, about 1.7 mg / kg, about 1.8 mg / kg, about 1.9 mg / kg, about 2.0 mg / kg, about 2.25 mg / kg, about 2.5 mg / kg, about 2.75 mg / kg, about 3.0 mg / kg, about 3.25 mg / kg, about 3.5 mg / kg, about 3.75 mg / kg, about 4.0 mg / kg, about 4.5 mg / kg, about 5.0 mg / kg, about 5.5 mg / kg, or about 6.0 mg / kg. In certain embodiments, the anti-c-Kit antibody is administered at a dose of about 0.1 mg / kg to about 4 mg / kg, or about .5 mg / kg to about 4.0 mg / kg, or about .5 mg / kg to about 2.0 mg / kg. In specific embodiments, JSP191 is administered at any of these doses. In specific embodiments, CDX0158 or CDX0159 is administered at any of these doses. In specific embodiments, FSI-174 is administered at any of these doses.
[0115] In some embodiments, a single dose of an anti-c-kit antibody as described herein is administered to a subject in need thereof. In some embodiments, two or more doses of an anti-c-kit antibody are administered to a subject.
[0116] In some embodiments, the anti-c-kit antibody is administered to the subject at a dosing schedule of about once a week, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, about every 9 weeks, about every 10 weeks, about every 11 weeks, about every 12 weeks, about every 13 weeks, about every 14 weeks, about every 15 weeks, about every 16 weeks, about every 17 weeks, about every 18 weeks, about every 19 weeks, or about every 20 weeks, or about once a month, once every two months, or once every three months. In some embodiments, the anti-c-kit antibody is administered to the subject at a dosing schedule in which the time intervals between each administration are different, for example, the subject can be administered a dose about once a week for about 4 weeks, followed by a dose about every 2 weeks for about 8 weeks, and combinations thereof. In one embodiment, the anti-c-kit antibody is administered to the subject about once every eight weeks for four cycles, for example, JSP191 is administered at about 0.3 mg / kg, 0.6 mg / kg, 0.9 mg / kg, or 1.2 mg / kg body weight. In certain embodiments, the anti-c-kit antibody is JSP191 and is administered at a dose of about 0.1 mg / kg to about 4 mg / kg, or about .5 mg / kg to about 4.0 mg / kg, or about .5 mg / kg to about 2.0 mg / kg, about 3.0 mg / kg, about 3.25 mg / kg, about 3.5 mg / kg, about 3.75 mg / kg, about 4.0 mg / kg, about 4.5 mg / kg, about 5.0 mg / kg, about 5.5 mg / kg, or about 6.0 mg / kg of the subject's body weight. In certain embodiments, JSP191 is administered to MDS (e.g., low-risk MDS) or AML patients once a month for about four months at a dose of about 0.1 mg / kg to about 4 mg / kg, or about .5 mg / kg to about 4.0 mg / kg, or about .5 mg / kg to about 2.0 mg / kg, about 3.0 mg / kg, about 3.25 mg / kg, about 3.5 mg / kg, about 3.75 mg / kg, about 4.0 mg / kg, about 4.5 mg / kg, about 5.0 mg / kg, about 5.5 mg / kg, or about 6.0 mg / kg of the subject's body weight.
[0117] In some embodiments, the anti-c-kit antibody is administered to the subject on a dosing schedule of about every month, about every 6 months, about every year, about every 2 years, about every 3 years, or about every 5 years. In some embodiments, as part of the dosing schedule, the subject is administered an initial dose or loading dose of the anti-c-kit antibody.
[0118] In some embodiments, the dosing regimen lasts about or at least one month, about or at least 6 months, about or at least one year, about or at least 2 years, about or at least 3 years, or about or at least 5 years. In some embodiments, the dosing regimen lasts until the subject is disease-free.
[0119] In some embodiments, anti-c-kit antibody treatment as described herein increases the percentage of healthy hematopoietic stem cells (HSCs) relative to the total HSCs in the subject's bone marrow to at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or at least 100% of all HSCs present in the subject's bone marrow.
[0120] In some embodiments, anti-c-kit antibody treatment is associated with a long-term predominance of healthy hematopoietic stem cells (HSCs) in the subject's bone marrow. As used herein, "long-term predominance" of healthy HSCs can refer to a long-term increase in the percentage of healthy HSCs in the bone marrow, as assessed after any period of time after treatment, for example, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years after treatment.
[0121] In some embodiments, the percentage of healthy hematopoietic stem cells following administration of anti-c-kit therapy is assessed by bone marrow biopsy, blood cell count, or blood film from the subject.
[0122] According to embodiments of the methods disclosed herein, monotherapy treatment with the anti-c-kit antibody is sufficient, and the subject does not need to be treated with another therapeutic agent for the disease being treated. In other embodiments, the subject is treated with an anti-c-kit antibody in combination with another chemotherapeutic agent or immunotherapy to treat the disease being treated.
[0123] In some embodiments, the subject administered an anti-c-kit therapy as described herein does not receive a hematopoietic cell transplant (HCT) within at least 4 months, at least 6 months, at least 1 year, at least 2 years, or any time period after administration of the anti-c-kit antibody.
[0124] In some embodiments, the subject administered an anti-c-kit therapy as described herein does not receive total body irradiation (TBI) within at least 4 months, at least 6 months, at least 1 year, at least 2 years, or any time period after administration of the anti-c-kit antibody.
[0125] In some embodiments, the subject administered an anti-c-kit therapy as described herein does not receive chemotherapy including but not limited to azacytidine, lenalidomide, decitabine, and / or rupatercept within at least 4 months, at least 6 months, at least 1 year, or at least 2 years, or any time period after administration of the anti-c-kit antibody.
[0126] In some embodiments, anti-c-kit treatment as described herein is associated with reduced side effects relative to other treatments, including but not limited to hematopoietic cell transplantation (HCT), total body irradiation (TBI) and / or chemotherapy. Fewer side effects can be measured by patient complaints, patient / doctor visits and / or the number of hospitalizations after treatment to determine. In some embodiments, reduced side effects include a lower risk of hematological toxicity and / or a lower risk of death from infection. In some embodiments, the methods disclosed herein result in reduced cytopenias compared to other treatments such as HCT.
[0127] In some embodiments, the anti-c-kit antibodies described herein can be administered as a combination therapy comprising an anti-CD47 antibody.
[0128] In some embodiments, an anti-c-kit antibody as described herein can be administered as a combination therapy comprising a chemotherapeutic agent (e.g., azacytidine, lenalidomide, decitabine, and / or rotaxep). In a specific embodiment, an anti-c-kit antibody (e.g., JSP-191) is administered to a subject in combination with azacytidine. The two agents can be administered at the same or different times, and in some embodiments, both agents are present in the subject for a period of time.
[0129] In some embodiments, anti-c-kit antibody therapy (or combination therapy) can be delivered orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonaryly, vaginally, rectally or intraocularly. In some embodiments, anti-c-kit antibodies (e.g., JSP191) are administered systemically, e.g., intravenously or subcutaneously. In some embodiments, anti-c-kit antibodies are delivered directly to the bone marrow.
[0130] IV. Pharmaceutical Compositions
[0131] In some embodiments, the anti-c-kit antibody (or combination therapy) is present in a pharmaceutical composition. In a specific embodiment, the pharmaceutical composition can be in a water-soluble form, such as a pharmaceutically acceptable salt, which means including acid and base addition salts. Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid. Pharmaceutically acceptable base addition salts include those derived from inorganic bases, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, etc. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
[0132] The pharmaceutical compositions described herein may also contain one or more of the following: carrier proteins, such as serum albumin; buffers; fillers, such as microcrystalline cellulose, lactose, corn starch and other starches; binders; and polyethylene glycol.
[0133] The composition for administration generally comprises an antibody dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, such as buffered saline. The composition may contain pharmaceutically acceptable auxiliary substances, such as those required for close physiological conditions, such as pH and buffers, toxic antagonists, such as sodium acetate, sodium chloride, potassium chloride, calcium chloride and sodium lactate. The concentration of the active agent in the preparation can vary, and according to the selected specific mode of administration and the needs of the patient, selection is made based on body fluid volume, viscosity and body weight (such as Remington's Pharmaceutical Science (15th edition, 1980) and Goodman and Gillman, The Pharmacological Basis of Therapeutics (Hardman et al., 1996)).
[0134] V. Kit
[0135] The present disclosure also provides a kit comprising an anti-c-kit antibody as described herein, such as a kit for administering an anti-c-kit antibody by a medical professional or a subject in need. The kit may include, for example, a container and one or more doses of an anti-c-kit antibody and instructions for use thereof. In certain embodiments, the kit includes multiple doses of an anti-c-kit antibody suitable for a dosing regimen within a time period. In certain embodiments, each dose comprises the same amount of an anti-c-kit antibody, while in other embodiments, the kit may include two or more different doses of an anti-c-kit antibody. In certain embodiments, each dose is present in a separate container. In a specific embodiment, each of the one or more doses comprises about 0.5 mg to about 800 mg of an anti-c-kit antibody, optionally about 5 mg to about 800 mg of an anti-c-kit antibody. In a specific embodiment, one or more doses comprise about 40 mg to about 50 mg, optionally about 45 mg of an anti-c-kit antibody. In a specific embodiment, one or more doses comprise about 140 mg to about 160 mg, optionally about 150 mg of an anti-c-kit antibody.
[0136] Example
[0137] Example 1
[0138] JSP191 as primary treatment for MDS and AML
[0139] A clinical study was conducted to demonstrate that treatment of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with the anti-c-kit antibody JSP191 is effective in depleting diseased stem and progenitor cells.
[0140] Nine patients with higher-risk MDS or AML were treated with a single dose of JSP191 at 0.6 mg / kg administered intravenously. Notably, JSP191 depleted 30-95% of diseased HSC cells (CD34+CD45RA-CD117+HSCs) 10-14 days after treatment ( Figure 2 In addition, in this ongoing clinical trial, intravenous administration of 0.6 mg / kg of JSP191 was safe and well tolerated. No obvious JSP191-related infusion reactions were observed, and no obvious adverse events were observed.
[0141] These studies suggest that, for patients who retain at least a small proportion of normal HSCs, treatment with anti-c-kit antibodies could serve as primary therapy to deplete diseased HSCs and allow replacement of diseased HSCs by hematopoiesis of healthy HSCs, such as Figure 1 shown.
[0142] Example 2
[0143] JSP191 as a second-line treatment for patients with lower-risk MDS
[0144] A Phase 1 clinical study was conducted to demonstrate that treatment of low-risk myelodysplastic syndrome (MDS) patients with the anti-c-kit antibody JSP191 is effective in depleting diseased stem and progenitor cells.
[0145] Four groups of MDS patients were treated with different doses of JSP191, including 0.3mg / kg (with a sentinel dose of 0.1mg / kg), 0.6mg / kg, 0.9mg / kg and 12mg / kg. MDS patients were given once every 8 weeks x 4 cycles. Each group included 3-6 patients. Patients had MDS with very low, low or moderate IPSS-R risk, i.e., patients with lower risk MDS. Patients had RBC transfusion dependence, thrombocytopenia or neutropenia.
[0146] It is expected that the study will show the safety and tolerability of JSP191 at these doses, as well as the efficacy and duration of response of HI-E / HI-P / HI-N, the reduction of RBC transfusions, the ORR and the duration of response of IWG 2006, and the progression-free survival. Hematopoietic improvement can be analyzed and demonstrated as described in Okamura et al., Leuk Res Rep. 2014; 3(1): 24-27. It is expected that treatment with JSP191 will lead to the depletion of diseased HSCs, followed by the recovery and expansion of healthy HSCs.
[0147] These studies are expected to demonstrate that, for low-risk MDS patients who retain at least a small fraction of normal HSCs, treatment with anti-c-kit antibodies can serve as primary therapy to deplete diseased HSCs and allow replacement of diseased HSCs by hematopoiesis of healthy HSCs, such as Figure 1 shown.
[0148] The various embodiments described above can be combined to provide further embodiments.
[0149] Aspects of the embodiments can be modified, if necessary, to employ concepts of the various patents, applications and publications to provide yet further embodiments.
[0150] These and other changes can be made to the embodiments in light of the above detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and claims, but should be construed to include all possible embodiments and the full scope of equivalents to which such claims are entitled. Therefore, the claims are not limited by the present disclosure.
[0151] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification and / or listed in the Application Data Sheet are incorporated herein by reference in their entirety.
Claims
1. A method for treating a hematopoietic stem cell (HSC) disease or condition in a subject, wherein the disease or condition is optionally myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), the method comprising administering to the subject an effective dose of an anti-c-kit antibody to achieve long-term presence or dominance of healthy HSCs in the subject's bone marrow.
2. The method of claim 1, wherein the method selectively depletes diseased HSCs compared to healthy HSCs.
3. The method of claim 1 or 2, wherein the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a monoclonal antibody selected from the group consisting of SR-1, JSP191, MGTA-117, FSI-174, CDX-0159, 8D7, K45, 104D2, CK6, AB249, YB5.B8, AF-2-1, AF11, AF12, AF112, AF-3, AF-1-1, NF, NF-2-1, NF11, NF12, NF112, NF-3, HF11, HF12, and HF112.
4. The method of any one of claims 1-3, wherein the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a humanized form of a monoclonal antibody selected from the group consisting of: ACK2, ACK4, 2B8, 3C11, MR-1, and CD122.
5. The method of any one of claims 1-4, wherein the anti-c-kit antibody comprises the CDRs of an antibody that blocks binding of stem cell factor (SCF) to stem cell factor receptor (CD117), optionally wherein the antibody is JSP191.
6. The method of any one of claims 1-5, wherein the subject is administered about 0.01 mg / kg to about 10 mg / kg of the anti-c-kit antibody, optionally about 0.1 mg / kg to about 10 mg / kg of the anti-c-kit antibody.
7. The method of any one of claims 1-5, wherein about 0.6 mg / kg of the anti-c-kit antibody is administered to the subject.
8. The method of any one of claims 1-5, wherein about 2 mg / kg of the anti-c-kit antibody is administered to the subject.
9. The method of any one of claims 1-8, wherein the subject's bone marrow comprises at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, or at least 20% healthy HSCs prior to treatment.
10. The method of any one of claims 1-9, wherein the disease or disorder is myelodysplastic syndrome (MDS).
11. The method of any one of claims 1-10, wherein the MDS is a lower risk MDS.
12. The method of any one of claims 1-10, wherein the disease or disorder is acute myeloid leukemia (AML).
13. The method of any one of claims 1-12, wherein the anti-c-kit antibody is delivered to the subject systemically, optionally wherein the anti-c-kit antibody is delivered intravenously or subcutaneously.
14. The method of any one of claims 1-12, wherein the anti-c-kit antibody is delivered locally to the subject, optionally wherein the anti-c-kit antibody is delivered directly to the bone marrow.
15. The method of any one of claims 1-14, wherein two or more doses of the anti-c-kit antibody are administered to the subject.
16. The method of claim 15, wherein one of the two or more doses is administered every week, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, every 11 weeks, or every 12 weeks, optionally wherein the time intervals between doses are different.
17. The method of any one of claims 1-16, wherein the subject has experienced failure of erythropoiesis stimulating agent (ESA) therapy, optionally wherein the ESA therapy comprises erythropoietin and / or darbepoetin.
18. The method of any one of claims 1-17, wherein the method has reduced side effects compared to treatment with a chemotherapeutic agent, optionally wherein the chemotherapeutic agent comprises azacytidine, lenalidomide, decitabine and / or rotercept.
19. The method of claim 18, wherein the reduced side effects are lower risk of hematological toxicity and lower risk of lethality from infection.
20. The method of any one of claims 1-19, wherein the method increases the percentage of normal HSCs in the bone marrow to at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 100% of all HSCs.
21. The method of any one of claims 1-20, wherein the subject has not undergone hematopoietic cell transplantation (HCT) within at least 4 months, at least 6 months, at least 1 year, or at least 2 years after administration of the anti-c-kit antibody.
22. The method of any one of claims 1-21, wherein the anti-c-kit antibody is administered in combination with an anti-CD47 antibody.
23. The method of any one of claims 1-22, wherein the anti-c-kit antibody is administered in combination with a chemotherapeutic agent.
24. The method of claim 23, wherein the chemotherapeutic agent is azacytidine.
25. A method for depleting endogenous diseased hematopoietic stem cells (HSCs) in a subject, comprising administering an anti-c-kit antibody to the subject, wherein the method results in an increase in the percentage of healthy hematopoietic stem cells (HSCs) present in the subject's bone marrow.
26. The method of claim 25, wherein the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a monoclonal antibody selected from the group consisting of SR-1, JSP191, MGTA-117, FSI-174, CDX0158, CDX0159, 8D7, K45, 104D2, CK6, AB249, YB5.B8, AF-2-1, AF11, AF12, AF112, AF-3, AF-1-1, NF, NF-2-1, NF11, NF12, NF112, NF-3, HF11, HF12, and HF112, optionally JSP191, CDX0158, CDX0159, or FSI-174.
27. The method of claim 25, wherein the anti-c-kit antibody comprises one or more complementarity determining regions (CDRs) present in a humanized form of a monoclonal antibody selected from the group consisting of: ACK2, ACK4, 2B8, 3C11, MR-1, and CD122.
28. The method of claim 25, wherein the anti-c-kit antibody comprises the CDRs of an antibody that blocks binding of stem cell factor (SCF) to stem cell factor receptor (CD117), optionally wherein the antibody is JSP191.
29. The method of any one of claims 25-28, wherein the subject is administered about 0.01 mg / kg to about 20 mg / kg of the anti-c-kit antibody, optionally about 0.1 mg / kg to about 10 mg / kg of the anti-c-kit antibody.
30. The method of any one of claims 25-28, wherein about 0.6 mg / kg of the anti-c-kit antibody is administered to the subject.
31. The method of any one of claims 25-28, wherein about 2 mg / kg of the anti-c-kit antibody is administered to the subject.
32. The method of claim 1, wherein the subject's bone marrow comprises at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, or at least 20% healthy HSCs prior to treatment.
33. The method of any one of claims 25-32, wherein the method is used to treat a disease or condition selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma, non-Hodgkin's lymphoma, clonal hematopoiesis of undetermined potential (CHIP), clonal cytopenias of undetermined significance (CCUS), myelodysplastic syndrome (MDS), idiopathic cytopenias of undetermined significance (ICUS), and myeloproliferative neoplasms (MPNs).
34. The method of claim 33, wherein the disease or condition is MDS.
35. The method of claim 34, wherein the MDS is a lower risk MDS.
36. The method of any one of claims 25-35, wherein the anti-c-kit antibody is delivered systemically to the subject, optionally wherein the anti-c-kit antibody is delivered intravenously or subcutaneously.
37. The method of any one of claims 25-35, wherein the anti-c-kit antibody is delivered locally to the subject, optionally wherein the anti-c-kit antibody is delivered directly to the bone marrow.
38. The method of any one of claims 25-37, wherein two or more doses of the anti-c-kit antibody are administered to the subject.
39. The method of claim 38, wherein one of the two or more doses is administered about every week, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, about every 9 weeks, about every 10 weeks, about every 11 weeks, or about every 12 weeks, optionally wherein the time intervals between each dose are different.
40. The method of any one of claims 25-39, wherein the subject has experienced failure of erythropoiesis stimulating agent (ESA) therapy, optionally wherein the ESA therapy comprises erythropoietin and / or darbepoetin.
41. The method of any one of claims 25-40, wherein the method has reduced side effects compared to treatment with a chemotherapeutic agent, optionally wherein the chemotherapeutic agent comprises azacytidine, lenalidomide, decitabine and / or rotercept.
42. The method of claim 41, wherein the reduced side effects include lower risk of hematologic toxicity and lower risk of lethality from infection.
43. The method of any one of claims 25-42, wherein the method increases the percentage of normal HSCs in the bone marrow to at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 100% of all HSCs, and optionally wherein the method results in long-term dominance of healthy hematopoietic stem cells (HSCs) in the subject's bone marrow.
44. The method of any one of claims 25-43, wherein the subject has not undergone hematopoietic cell transplantation (HCT) within at least 4 months, at least 6 months, at least 1 year, or at least 2 years after administration of the anti-c-kit antibody.
45. A kit comprising one or more doses of an anti-c-kit antibody.
46. The kit of claim 45, wherein each of the one or more doses comprises about 0.5 mg to about 800 mg of the anti-c-kit antibody, optionally about 5 mg to about 800 mg of the anti-c-kit antibody.
47. The kit of claim 46, wherein the kit comprises one or more doses comprising about 40 mg to about 50 mg, optionally about 45 mg, of the anti-c-kit antibody.
48. The kit of claim 46, wherein the kit comprises one or more doses comprising about 140 mg to about 160 mg, optionally about 150 mg of the anti-c-kit antibody.
